Scott Brun
Bruns is in his current position since 2019. Previously, he joined AbbeVie Inc. at its launch in 2013 as VP and head of pharmaceutical development and most recently served as VP of scientific affairs and head of AbbVie Ventures. Earlier, he spent 10 years at Abbott Laboratories, most recently as divisional VP of infectious disease development.
- March 2020
Added to: Axial Biotherapeutics - Walthem, MA
Axial is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of the central nervous system (specifically Parkinson's disease and Autism Spectrum disorders) and other gut-derived diseases